title: New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus.
abstract: Everolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who developed disfiguring oral and perianal ulcers secondary to everolimus's toxicity. This is probably the first report of perianal involvement. Dermatologists need to be aware of the potential mucocutaneous adverse effects related to these new drugs that are becoming evermore common in our clinical practice.
authors: Universidade Federal de São Paulo, São Paulo, BR.
authors: Victor Pavan
authors: VP
authors: Pasin
authors: Universidade Federal de São Paulo, São Paulo, BR.
authors: Amanda Regio
authors: AR
authors: Pereira
authors: Universidade Federal de São Paulo, São Paulo, BR.
authors: Kalline Andrade de
authors: KA
authors: Carvalho
authors: Universidade Federal de São Paulo, São Paulo, BR.
authors: João Marcos Góes de
authors: JM
authors: Paiva
authors: Universidade Federal de São Paulo, São Paulo, BR.
authors: Milvia Maria Simões e Silva
authors: MM
authors: Enokihara
authors: Universidade Federal de São Paulo, São Paulo, BR.
authors: Adriana Maria
authors: AM
authors: Porro
mesh_terms: D000328:Adult; D001004:Anus Diseases / Q000139:chemically induced* / Q000473:pathology; D000068338:Everolimus / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007121:Immunocompetence / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D009055:Mouth / Q000473:pathology; D012883:Skin Ulcer / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D013280:Stomatitis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases